3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Conditions
Arthritis, Rheumatoid
7
Spondylitis, Ankylosing
2
Psoriasis
2
Colitis, Ulcerative
2
Sarcoidosis
1
Plaque Psoriasis
1
Nephrotic Syndrome
1
Nephrosis, Lipoid
1
Mucopolysaccharidosis VI
1
Mucopolysaccharidosis II
1
Mucopolysaccharidosis I
1
Mucopolysaccharidoses
1
Macular dystrophy, corneal type 1
1
Kidney Diseases
1
Inflammation
1
Hidradenitis Suppurativa
1
Glomerulosclerosis, Focal Segmental
1
Dupuytren Contracture
1
Crohn Disease
1
Arthritis, Psoriatic
1
Acne Vulgaris
1
Abscess
1
Interventions
tofacitinib
7
Etanercept
4
Methotrexate
2
Adalimumab
2
sodium luminolate
1
secukinumab
1
ixekizumab
1
baricitinib
1
apremilast
1
abrocitinib
1
Vitamin D
1
Vaccines
1
Saline Solution
1
Herpes Zoster Vaccine
1
Folic Acid
1
Fish Oils
1
Fatty Acids, Omega-3
1
Eicosapentaenoic Acid
1
Docosahexaenoic Acids
1
Cholecalciferol
1
Anti-Infective Agents, Local
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Psoriasis
×
Adalimumab
×
Clear all
NCT02196701
2018-03-19
CLEAR
AbbVie
Phase 3
Completed
46 enrolled
27 charts
NCT00932113
2017-08-31
MOA
Tufts Medical Center
Phase 4
Completed
33 enrolled
11 charts